公开(公告)号：EP3099708A4

公开(公告)日：2017-07-05

申请号：EP15744002

申请日：2015-01-28

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  OCHI TOSHIKI

IPC: C07K14/725 ,  A61K38/17 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02

CPC classification number: C07K14/7051 ,  A61K38/00 ,  C12N15/1037 ,  C12N15/1055

Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.

Abstract translation: 提供了一种确定可形成对感兴趣肽特异的TCR的TCR多肽链的方法。 还提供了用于产生表达对感兴趣肽特异的T细胞受体（TCR）的细胞的方法和组合物，用于产生TCR链核酸和/或TCR链多肽对和/或编码 TCR，包含携带编码通过所述方法获得的TCR的核酸的细胞的细胞群，以及用于治疗病症的方法，所述方法包括向所述受试者施用所述细胞群。

公开(公告)号：BR112022001710A2

公开(公告)日：2022-06-21

申请号：BR112022001710

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： SUGATA KENJI ,  HIRANO NAOTO

IPC: A61K38/17 ,  A61P35/00 ,  C07K14/74 ,  C12N5/07 ,  C12N15/12 ,  G01N33/567

Abstract: moléculas mhc classe ii e métodos de uso das mesmas. a presente invenção refere-se a moléculas hla de classe ii tendo uma afinidade maior para cd4 do que as moléculas hla de classe ii que ocorrem naturalmente. em certos aspectos, a molécula hla de classe ii compreende uma cadeia dq beta tendo (i) um aminoácido que não leucina em uma posição correspondente ao resíduo de aminoácido 114 da seq id no: 1, (ii) um aminoácido que não a valina em uma posição correspondente ao resíduo de aminoácido 143 da seq id no: 1, (iii) ou ambos (i) e (ii). certos aspectos da presente invenção referem-se a moléculas de ácido nucleico que codificam as moléculas hla de classe ii, vetores compreendendo a molécula de ácido nucleico, células que compreendem as mesmas, e métodos de uso das mesmas.

公开(公告)号：BR112022001688A2

公开(公告)日：2022-05-24

申请号：BR112022001688

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： SASO KAYOKO ,  SUGATA KENJI ,  HIRANO NAOTO

IPC: C07K14/725 ,  A61K35/17 ,  A61P35/00 ,  C12N15/867

Abstract: receptores de células t e métodos de uso dos mesmos. a presente invenção é dirigida refere-se a receptores de células t recombinantes capazes de ligar um epítopo ccd1 e moléculas de ácido nucleico que codificam os mesmos. em alguns aspectos, as moléculas de ácido nucleico compreendem ainda uma segunda sequência de nucleotídeos, em que a segunda sequência de nucleotídeos ou o polipeptídeo codificado pela segunda sequência de nucleotídeos inibe a expressão de um tcr endógeno. outros aspectos da invenção são dirigidos a vetores que compreendem a molécula de ácido nucleico e células que compreendem o tcr recombinante, a molécula de ácido nucléico, ou o vetor. ainda outros aspectos da invenção são dirigidos a métodos de utilização dos mesmos. em alguns aspectos, os métodos compreendem o tratamento de um câncer em um indivíduo em necessidade do mesmo.

公开(公告)号：MX2022001204A

公开(公告)日：2022-05-03

申请号：MX2022001204

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ

IPC: G01N33/566 ,  C07K14/73 ,  C12N15/12

Abstract: La presente descripción hace referencia a métodos de identificación de receptores de linfocitos T (TCR) específicos de MHC de clase II. En determinados aspectos, el método comprende poner un linfocito T en contacto con un complejo que comprende (i) una molécula de MHC de clase II que tiene una mayor afinidad por CD4 que las moléculas de MHC de clase II de origen natural y (ii) un péptido, por ejemplo, un epítopo. En determinados aspectos, la molécula de HLA de clase II comprende una cadena beta que tiene una o más mutaciones con respecto a una secuencia de cadena beta de tipo salvaje.

公开(公告)号：MX2021010543A

公开(公告)日：2021-12-15

申请号：MX2021010543

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: La presente descripción se refiere a receptores de linfocitos T recombinantes capaces de unirse a un epítopo de NY-ESO-1 y moléculas de ácido nucleico que los codifican. En algunas modalidades, las moléculas de ácido nucleico comprenden además una segunda secuencia de nucleótidos, donde la segunda secuencia de nucleótidos o el polipéptido codificado por la segunda secuencia de nucleótidos inhibe la expresión de un TCR endógeno. Otros aspectos de la descripción se refieren a vectores que comprenden la molécula de ácido nucleico y células que comprenden el TCR recombinante, la molécula de ácido nucleico o el vector. Otros aspectos adicionales de la descripción se refieren a métodos para usarlos. En algunas modalidades, los métodos comprenden tratar un cáncer en un sujeto que lo necesita.

公开(公告)号：SG11202109593SA

公开(公告)日：2021-10-28

申请号：SG11202109593S

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/12 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：SG11202109590VA

公开(公告)日：2021-10-28

申请号：SG11202109590V

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020231928A1

公开(公告)日：2021-10-07

申请号：AU2020231928

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  A61P37/04 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020231106A1

公开(公告)日：2021-10-07

申请号：AU2020231106

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/12 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020231693A1

公开(公告)日：2021-09-30

申请号：AU2020231693

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.